167 related articles for article (PubMed ID: 109202)
1. The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II).
Vogl SE; Berenzweig M; Kaplan BH; Moukhtar M; Bulkin W
Cancer Treat Rep; 1979 Feb; 63(2):311-7. PubMed ID: 109202
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma.
Kane R; Harvey H; Andrews T; Bernath A; Curry S; Dixon R; Gottlieb R; Kukrika M; Lipton A; Mortel R; Ricci J; White D
Cancer Treat Rep; 1979 Feb; 63(2):307-9. PubMed ID: 109201
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy for alkylator-resistant ovarian carcinoma: a preliminary report of a Southwest Oncology Group trial.
Alberts DS; Hilgers RD; Moon TE; Martimbeau PW; Rivkin S
Cancer Treat Rep; 1979 Feb; 63(2):301-5. PubMed ID: 109200
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy for ovarian carcinoma with cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum(II) after failure of initial chemotherapy.
Bruckner HW; Ratner LH; Cohen CJ; Wallach R; Kabakow B; Greenspan EM; Holland JF
Cancer Treat Rep; 1978 Jul; 62(7):1021-3. PubMed ID: 688244
[TBL] [Abstract][Full Text] [Related]
7. Cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin (CHAD) as second-line chemotherapy for ovarian adenocarcinoma.
Piver MS; Lele S; Barlow JJ
Cancer Treat Rep; 1981; 65(1-2):149-51. PubMed ID: 6784921
[TBL] [Abstract][Full Text] [Related]
8. Advanced ovarian cancer: brief intensive combination chemotherapy and second-look operation.
Greco FA; Julian CG; Richardson RL; Burnett L; Hande KR; Oldham RK
Obstet Gynecol; 1981 Aug; 58(2):199-205. PubMed ID: 6789265
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy of advanced ovarian cancer with hexamethylmelamine, cis-Platinum, and doxorubicin after failure of prior therapy.
Vogl SE; Pagano M; Kaplan BH; Einhorn N; Arseneau J; Moukhtar M; Greenwald E
Obstet Gynecol; 1980 Nov; 56(5):635-40. PubMed ID: 6776457
[TBL] [Abstract][Full Text] [Related]
10. Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.
Young RC; Chabner BA; Hubbard SP; Fisher RI; Bender RA; Anderson T; Simon RM; Canellos GP; DeVita VT
N Engl J Med; 1978 Dec; 299(23):1261-6. PubMed ID: 101843
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
12. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
13. Treatment of advanced ovarian carcinoma with a combination of hexmethylmelamine, cyclophosphamide, methotrexate, and 5-fluorourcil (hexa-CAF) in patients with and without previous treatment.
Neijt JP; van Lindert AC; Vendrik CP; Roozendaal KJ; Struyvenberg A; Pinedo HM
Cancer Treat Rep; 1980; 64(2-3):323-6. PubMed ID: 6773656
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for testicular cancer: current status of the National Cancer Institute Combined Modality Trial.
Anderson T; Javadpour N; Schilsky R; Barlock A; Young RC
Cancer Treat Rep; 1979; 63(9-10):1687-92. PubMed ID: 91439
[TBL] [Abstract][Full Text] [Related]
15. cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer.
Young RC; Von Hoff DD; Gormley P; Makuch R; Cassidy J; Howser D; Bull JM
Cancer Treat Rep; 1979; 63(9-10):1539-44. PubMed ID: 387224
[TBL] [Abstract][Full Text] [Related]
16. Sequential combination chemotherapy and surgery for disseminated testicular cancer: cis-dichlorodiammineplatinum(II), vinblastine, and bleomycin remission-induction therapy followed by cyclophosphamide and adriamycin.
Garnick MB; Canellos GP; Richie JP; Stark JJ
Cancer Treat Rep; 1979; 63(9-10):1681-6. PubMed ID: 91438
[TBL] [Abstract][Full Text] [Related]
17. [Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].
de Gramont A; Drolet Y; Louvet C; Dray C; Krulik M; Pigné A; Lavoie A; Painchaud M; Blouin R; Tessier C
J Gynecol Obstet Biol Reprod (Paris); 1986; 15(1):105-9. PubMed ID: 3084619
[TBL] [Abstract][Full Text] [Related]
18. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
[No Abstract] [Full Text] [Related]
19. Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide: a preliminary report.
Ehrlich CE; Einhorn L; Williams SD; Morgan J
Cancer Treat Rep; 1979 Feb; 63(2):281-8. PubMed ID: 376134
[No Abstract] [Full Text] [Related]
20. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
